Trump drug loophole; Gilead buys Ouro for $2.18B
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Chris Klomp said the most‑favored‑nation deals aim to raise new‑drug prices abroad rather than cut U.S. prices.
- Rachel Sachs warned that manufacturers could delay foreign launches, preventing verification of U.S. most‑favored‑nation pricing until after the deals expire.
- Gilead Sciences announced a plan to acquire autoimmune‑disease developer Ouro Medicines for up to $2.18 billion.
- Gilead Sciences disclosed a R&D partnership with Galapagos under which Galapagos will fund half of the upfront payment and half of any milestone payments for Ouro’s assets.
- Gilead Sciences holds roughly a 25 % stake in Galapagos and can access Galapagos’s drug‑discovery platform through a standing agreement.
- Gilead Sciences said the Ouro acquisition will bolster its growing inflammation portfolio.
Why it matters: The loophole lets drugmakers postpone foreign launches, preventing the administration’s pricing rule from curbing U.S. drug costs and keeping prices high for patients in the U.S. market, while Gilead’s $2.18 billion purchase of Ouro expands its autoimmune‑therapy pipeline and bolsters its inflammation portfolio.
Ask SkimNews
